Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended September 30, 2026
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File No. 001-39110
ONTO INNOVATION INC.
(Exact name of registrant as specified in its charter)
Delaware
94-2276314
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
16 Jonspin Road, Wilmington, Massachusetts 01887
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (978) 253-6200
Securities registered pursuant to Section 12(b) of the Act
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value per share
ONTO
New York Stock Exchange (NYSE)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of outstanding shares of the registrant’s Common Stock on October 30, 2026 was 49,084,327.
TABLE OF CONTENTS
Item No.
Page
PART I FINANCIAL INFORMATION
Item 1.
Financial Statements (unaudited)
1
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and September 27, 2025
Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2026 and September 27, 2025
2
Condensed Consolidated Balance Sheets at September 30, 2026 and January 3, 2026
3
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and September 27, 2025
4
Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and September 27, 2025
5
Notes to Condensed Consolidated Financial Statements
7
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
23
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
30
Item 4.
Controls and Procedures
PART II OTHER INFORMATION
Legal Proceedings
Item 1A.
Risk Factors
Unregistered Sales of Equity Securities and Use of Proceeds
31
Defaults Upon Senior Securities
Mine Safety Disclosures
Item 5.
Other Information
Item 6.
Exhibits
32
Signatures
Item 1. Financial Statements
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 27,
2026
2025
Revenue
$
409,748
218,193
1,044,826
738,397
Cost of revenue
185,266
107,570
490,701
362,419
Gross profit
224,482
110,623
554,125
375,978
Operating expenses:
Research and development
45,068
32,493
119,045
95,815
Sales and marketing
23,858
17,103
68,422
51,729
General and administrative
39,231
24,820
104,900
72,608
Amortization
19,699
8,445
59,098
25,336
Restructuring and other
1,177
4,074
10,147
11,421
Total operating expenses
129,033
86,935
361,612
256,909
Operating income
95,449
23,688
192,513
119,069
Other income, net
Unrealized gain (loss) on investment in Rigaku
(40,841
)
—
Interest income, net
11,671
9,290
22,018
27,187
Foreign currency exchange losses
(1,352
(397
(1,952
(2,308
Other (expense) income, net
60
(602
(203
(571
Total other income, net
(30,462
8,291
(20,978
24,308
Income before provision for income taxes
64,987
31,979
171,535
143,377
Provision for income taxes
18,141
3,755
30,837
17,147
Net income
46,846
28,224
140,698
126,230
Earnings per share:
Basic
0.96
0.58
2.85
2.57
Diluted
0.95
0.57
2.83
Weighted average number of shares outstanding:
49,048
49,023
49,410
49,044
49,256
49,106
49,657
49,178
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
Other comprehensive (loss) income, net of tax:
Change in net unrealized (losses) gains on available-for-sale marketable securities
(1,035
191
(2,036
423
Change in currency translation adjustments
3,565
(1,864
1,538
7,017
Total other comprehensive (loss) income, net of tax
2,530
(1,673
(498
7,440
Total comprehensive income
49,376
26,551
140,200
133,670
CONDENSED CONSOLIDATED BALANCE SHEETS
September 30,2026
January 3,2026
ASSETS
Current Assets:
Cash and cash equivalents
400,677
346,119
Marketable securities
850,794
293,503
Accounts receivable, net of allowance of $2,321 at September 30, 2026 and $2,462 at January 3, 2026.
384,481
268,932
Inventories, net
424,180
298,264
Prepaid expenses and other current assets, net
46,155
61,217
Total current assets
2,106,287
1,268,035
Property, plant and equipment, net
121,498
127,184
Goodwill
625,848
644,015
Identifiable intangible assets, net
239,000
298,098
Investment in Rigaku
678,707
Deferred income taxes
3,323
3,864
Other assets
28,310
26,545
Total assets
3,802,973
2,367,741
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
140,020
107,685
Accrued liabilities
70,852
48,544
Deferred revenue
45,457
31,781
Other current liabilities
54,502
30,936
Total current liabilities
310,831
218,946
2031 Notes, net
1,473,179
―
Deferred and other tax liabilities
5,544
20,401
Other non-current liabilities
34,120
27,747
Total liabilities
1,823,674
267,094
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value, 97,000 shares authorized, 49,084 and 49,702 issued and outstanding at September 30, 2026 and January 3, 2026, respectively.
50
Additional paid-in capital
1,105,285
1,366,833
Accumulated other comprehensive loss
(10,519
(10,021
Accumulated earnings
884,483
743,785
Total stockholders’ equity
1,979,299
2,100,647
Total liabilities and stockholders’ equity
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Cash flows from operating activities:
Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities:
Amortization of intangibles
Accretion of discount on marketable securities
(6,546
(4,292
Depreciation
17,440
15,174
Share-based compensation
25,831
20,378
Provision for inventory valuation
5,614
20,385
Unrealized (gain) loss on investment in Rigaku
40,841
5,246
(14,509
Amortization of debt discount and issuance costs
2,130
Other, net
2,303
4,624
Changes in operating assets and liabilities
(126,076
39,993
Net cash and cash equivalents provided by operating activities
166,579
233,319
Cash flows from investing activities:
Purchases of marketable securities
(987,789
(421,154
Proceeds from maturities and sales of marketable securities
435,033
684,526
Purchases of property, plant and equipment
(8,803
(23,384
Purchase of investment in Rigaku
(719,548
Purchases of non-marketable equity securities
(8,000
Acquisition related adjustments
6,499
(57
Net cash and cash equivalents provided by (used in) investing activities
(1,274,608
231,931
Cash flows from financing activities:
Purchases and retirement of common stock
(204,979
(75,015
Tax payments related to shares withheld for share-based compensation plans
(16,602
(12,589
Issuance of shares through share-based compensation plans
5,927
9,740
Payment for bridge commitment fees
(3,750
Proceeds from issuance of 2031 Notes, net of issuance costs
1,471,049
Payment for capped call options
(88,950
Net cash and cash equivalents provided by (used in) financing activities
1,162,695
(77,864
Effect of exchange rate changes on cash and cash equivalents
(108
2,754
Net increase in cash and cash equivalents
54,558
390,140
Cash and cash equivalents at beginning of period
212,945
Cash and cash equivalents at end of period
603,085
Supplemental disclosure of cash flow information:
Income taxes paid (net of refunds)
6,872
35,468
Supplemental noncash disclosure of cash flow information:
Unpaid excise tax on repurchases of common stock
2,050
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
Common Stock
Additional Paid-in
AccumulatedOtherComprehensive
Accumulated
Shares
Amount
Capital
Loss
Earnings
Total
Balance at January 3, 2026
49,702
33,750
7,011
Issuance of shares through share-based compensation plans, net
73
Purchases of common stock
Share-based compensation plan withholdings
(31
(6,701
Currency translation
(1,860
Unrealized loss on investments
(659
Balance at March 31, 2026
49,744
1,367,143
(12,540
777,535
2,132,188
60,102
10,015
124
(805
(207,029
Capped call option purchase, net of tax impact
(69,675
(30
(8,361
(167
(342
Balance at June 30, 2026
49,033
1,098,020
(13,049
837,637
1,922,658
8,805
58
(7
(1,540
Balance at September 30, 2026
49,084
Balance at December 28, 2024
49,238
49
1,275,146
(13,863
664,550
1,925,882
64,095
6,814
140
4,179
(492
(17,491
(57,524
(49
(8,684
2,013
Unrealized gain on investments
338
Balance at March 29, 2025
48,837
1,259,964
(11,512
671,121
1,919,622
33,911
6,678
137
(37
(3,707
6,868
(106
Balance at June 28, 2025
48,937
1,262,935
(4,750
705,032
1,963,266
6,886
76
5,561
(4
(198
Balance at September 27, 2025
49,009
1,275,184
(6,423
733,256
2,002,066
6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1. Basis of Presentation
The accompanying interim unaudited Condensed Consolidated Financial Statements have been prepared by Onto Innovation Inc. (the “Company,” “Onto Innovation,” “we,” “our” or “us”) and in the opinion of management reflect all adjustments, consisting of normal recurring accruals, necessary for their fair presentation in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain reclassifications have been made to prior-period amounts to conform to current-period presentation. The interim results for the three and nine month periods ended September 30, 2026 are not necessarily indicative of results to be expected for the entire year or any future periods. This interim financial information should be read in conjunction with the financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2026 (the “2025 Form 10-K”) filed with the Securities and Exchange Commission on February 24, 2026. The accompanying Condensed Consolidated Balance Sheet at January 3, 2026 has been derived from the audited consolidated financial statements included in the 2025 Form 10-K.
On February 18, 2026, the Company’s Board of Directors (“Board”) changed the Company’s fiscal year-end from a 52-53-week fiscal year ending on the Saturday closest to December 31 to a December 31 fiscal year-end. The Company made the fiscal year change on a prospective basis and will not adjust operating results for prior periods. Additionally, the Company has adopted calendar quarter fiscal period ends commencing with the first quarter ended March 31, 2026. The change affects the prior year comparability of the Company’s fiscal quarters in 2025 and has resulted in shifts in the quarterly periods, which is not expected to have a material impact on our quarterly financial results. Our fiscal year ended January 3, 2026 was a 53-week fiscal year. The third quarter of the fiscal year ended January 3, 2026 ended on September 27, 2025. Throughout this document, the three month period ended September 30, 2026 represents the quarterly period that commenced on July 1, 2026, and ended on September 30, 2026. The three month period ended September 27, 2025 represents the quarterly period that commenced on June 29, 2025 and ended on September 27, 2025. The nine month period ended September 30, 2026 represents the period that commenced on January 4, 2026, the first day of our fiscal year, and ended on September 30, 2026. The nine month period ended September 27, 2025 represents the period that commenced on December 29, 2024 and ended on September 27, 2025.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates made by management include excess and obsolete inventory, fair value of assets acquired and liabilities assumed in a business combination, recoverability and useful lives of property, plant and equipment and identifiable intangible assets, recoverability of goodwill, recoverability of deferred tax assets, allowance for credit losses, liabilities for product warranty, share-based payments and liabilities for tax uncertainties. Actual results could differ from those estimates.
These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material.
Significant Accounting Policies
In addition to the significant accounting policies disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2026, the Company has adopted the following accounting policy during the period.
Equity Investments
Investments in equity securities in which a company has the ability to exercise significant influence, but not control, are accounted for under the equity method in accordance with ASC 323, Investments - Equity Method and Joint Ventures, unless the company elects the fair value option under ASC 825, Financial Instruments. The fair value option may be elected on an instrument-by-instrument basis, must be elected at initial recognition, and is irrevocable once made.
For equity securities for which the fair value option has been elected, the investment is measured at fair value at each reporting date, with all changes in fair value recognized in net income. For investments denominated in foreign currency, the investment is remeasured to U.S. dollars at the closing spot exchange rate at each reporting date, and the change in the U.S. dollar fair value attributable to both the change in the security’s quoted price and the change in exchange rates is recognized in net income without bifurcation. No amounts related to these investments are recorded in other comprehensive income. Dividends are recognized as income when the Company’s right to receive payment is established and do not reduce the carrying amount of the investment.
Upon initial recognition, the Company elected the fair value option for its investment in Rigaku Holdings Corporation (“Rigaku”). For further information, see Note 2, “Acquisitions and Investments,” and Note 3, “Fair Value Measurements.”
Recent Accounting Pronouncements
Recently Adopted or Effective
In December 2025, the FASB issued ASU 2025-12, “Codification Improvements,” which addresses suggestions received from stakeholders regarding the ASC and makes other incremental improvements to U.S. GAAP. The update represents changes to the ASC that clarify, correct errors in or make other improvements to a variety of topics that are intended to make it easier to understand and apply. The amendments in this update are effective for the Company beginning January 1, 2027, with early adoption permitted. The Company adopted this ASU during the quarter ended June 30, 2026. In connection with the adoption, the Company elected an accounting policy to allocate the excess of the repurchase price over par for all shares repurchased and retired to additional paid-in capital on a prospective basis.
In July 2025, the FASB issued ASU 2025-05, “Financial Instruments - Credit Losses (Topic 326),” which simplifies the estimation of credit losses on current accounts receivable and current contract assets arising from transactions accounted for under Accounting Standards Codification 606, Revenue from Contracts with Customers. The guidance allows all entities to use a practical expedient to assume that the current conditions as of the balance sheet date will remain unchanged for the remaining life of the asset when developing a reasonable and supportable forecast as part of estimating expected credit losses on these assets. The guidance is effective for fiscal years beginning after December 15, 2025, and interim periods within those fiscal years. Early adoption is permitted. Entities that elect the practical expedient are required to apply the amendments prospectively. The Company adopted this ASU during the quarter ended March 31, 2026 and elected the practical expedient. The adoption did not have a material impact on the condensed consolidated financial statements.
Updates Not Yet Effective
In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements,” to clarify and reorganize U.S. GAAP interim reporting guidance to improve navigability, applicability, and consistency without changing the fundamental nature or volume of required interim disclosures. This amendment clarifies when ASC 270 is applicable, establishes a disclosure principle requiring disclosure of material events or changes occurring since the most recent annual reporting period, and consolidates into ASC Topic 270 a comprehensive list of interim disclosures required by other codification topics. The amendment also clarifies the form and content of interim financial statements, including guidance for condensed interim reporting. The amendment is effective for the Company for interim periods in 2028, with early adoption permitted. The impact of the adoption of the amendments in this update is not expected to be material to the Company’s consolidated financial position and results of operations.
In December 2025, the FASB issued ASU 2025‑10, “Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities,” to establish specific guidance for the recognition, measurement, presentation, and disclosure of government grants received to reduce diversity and increase consistency amongst business entities in accounting for such grants. This amendment amends ASC Topic 832 to require that a government grant received by a business entity should not be recognized as income until it is probable that a business entity will comply with the conditions attached to the grant and the grant will be received, with any grant related to an asset to be purchased, constructed or acquired such as long-lived assets or inventory to be recognized on the balance sheet as either deferred income or as an adjustment to the cost basis of the related asset, or the cost accumulation approach, as such costs are incurred. Any grant income or deferred income shall be recognized in earnings on a systematic and rational basis over the periods in which a business entity recognizes as expenses the costs for which the grant is intended to compensate, whereas any grants accounted for using the cost accumulation approach will not have a direct subsequent recognition in earnings, but rather reduced depreciation or amortization in accounting for the related asset. Entities are also required to present grants recognized in earnings separately under other income or deducted from the related expense, and provide disclosures of the nature of the government grant received, the accounting policies used to account for the grant, and the significant terms and conditions of the grant. The amendment is effective for the Company for annual and interim periods in 2029, with early adoption and multiple transition methods permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.
8
In December 2025, the FASB issued ASU 2025-09, “Derivatives and Hedging (Topic 815): Hedge Accounting Improvements,” to amend certain aspects of its hedge accounting guidance to better reflect an entity’s risk management activities in the financial statements. The guidance expands the hedged risks permitted to be aggregated in a group of individual forecasted transactions and increases the variable price components eligible to be designated as the hedged risk in the forecasted purchase or sale of nonfinancial assets. For public business entities, the provisions of ASU 2025-09 are effective for fiscal years beginning after December 15, 2026. Early adoption is permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.
In September 2025, the FASB issued ASU 2025-06, “Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software,” which removes all references to software development stages and clarifies the threshold entities apply to begin capitalizing costs. ASU 2025-06 is effective for annual periods beginning after December 15, 2027 and interim reporting periods within those annual reporting periods. The ASU may be applied prospectively, retrospectively or through a modified transition approach with early adoption permitted. The Company is currently evaluating the potential impact of this standard on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40),” which requires additional disclosure of certain costs and expenses, including inventory purchases, employee compensation, selling expense and depreciation expense within the notes to financial statements. The guidance is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact that the updated standard will have on its financial statements and related disclosures.
NOTE 2. Acquisitions and Investments
On August 10, 2026, the Company completed the previously announced acquisition of 61,123,436 shares (27% of the issued and outstanding shares) of common stock of Rigaku for $719.5 million from Atom Investment, L.P., an affiliate of The Carlyle Group (the “Rigaku Transaction”), funded with a portion of the net proceeds from the issuance and sale of the Company’s 0.00% Convertible Senior Notes due 2031 (“2031 Notes”) and cash on hand. Rigaku’s common stock is listed on the Tokyo Stock Exchange. In connection with the Rigaku Transaction, the Company received the right to nominate one director to Rigaku’s board of directors.
The Company’s 27% ownership interest results in a presumption of significant influence under ASC 323, Investments - Equity Method and Joint Ventures. At initial recognition, the Company irrevocably elected the fair value option under ASC 825, Financial Instruments, for its investment in Rigaku. The Company elected the fair value option because Rigaku’s shares are publicly traded and have a readily determinable fair value, and management believes fair value provides the most relevant and transparent measure of the economic value of the investment. The Company does not control Rigaku and does not consolidate Rigaku’s financial results.
The investment in Rigaku is presented as “Investment in Rigaku,” a non-current asset, on the Condensed Consolidated Balance Sheets. The investment is remeasured to fair value at each reporting date based on the quoted market price of Rigaku’s common stock on the Tokyo Stock Exchange, translated into U.S. dollars at the closing spot exchange rate. All changes in the U.S. dollar fair value of the investment, including amounts attributable to changes in Rigaku’s share price and changes in the Japanese yen to U.S. dollar exchange rate, are recognized in net income within “Unrealized gain (loss) on investment in Rigaku” under “Other income, net” in the Condensed Consolidated Statements of Operations. The components are not bifurcated, and no amounts related to this investment are recorded in other comprehensive income. Dividends declared by Rigaku, if any, are recognized as dividend income when the Company’s right to receive payment is established and do not reduce the carrying amount of the investment.
Under the fair value option, the Company does not recognize its proportionate share of Rigaku’s net income or loss, amortization of acquisition-date basis difference, or equity method adjustments for Rigaku’s other comprehensive income items. Changes in the fair value of the investment are recognized currently in net income but are not taxable or deductible until realized. The resulting difference between the carrying amount of the investment and its tax basis is a temporary difference, for which the Company recognizes deferred taxes.
The following table summarizes the activity in the Company’s investment in Rigaku:
9
September 30, 2026
(in thousands)
Balance, beginning of the period
Initial recognition at acquisition date
719,548
Balance, end of period
The following table presents the unrealized gain (loss) on the Company’s investment in Rigaku recognized in net income:
Unrealized gain (loss) on investment in Rigaku still held at the reporting date
Total unrealized gain (loss) on investment in Rigaku
All amounts presented above relate to the investment in Rigaku, which was held as of September 30, 2026. No amounts were realized through sale during the three and nine months ended September 30, 2026. The Company recognized $3.4 million and $5.1 million of costs directly related to the Rigaku Transaction during the three and nine months ended September 30, 2026, respectively, which are recorded in “General and administrative” expense.
The Company evaluates the significance of its investment in Rigaku under Regulation S-X. The investment has not met the 20% significance threshold. Summarized income statement information of Rigaku is not required to be presented in this Form 10-Q under Rule 10-01(b)(1).
Completed Acquisition
On November 17, 2025 (the “Acquisition Date”), the Company completed the previously announced acquisition of Semilab USA LLC (“Semilab USA”), pursuant to the Equity Purchase Agreement (the “Purchase Agreement”), dated as of June 27, 2025, by and among the Company, Semilab International Zrt. (the “Seller”), Semilab Zrt. and Semilab USA, as amended by the Amendment to Equity Purchase Agreement, dated October 9, 2025.
The preliminary Acquisition Date fair value of consideration transferred consisted of the following:
At Acquisition Date
(in thousands, except per share data)
Cash paid
382,873
Issuance of common stock (1)
81,697
Cash paid to extinguish Semilab USA’s debt
55,892
Total purchase consideration
520,462
(1) The fair value is based on the issuance of 641,771 shares of the Company’s common stock, par value $0.001 per share ("Common Stock") with a per share value of $127.30 on the Acquisition Date.
The Company accounted for the acquisition of Semilab USA in accordance with ASC Topic 805, Business Combinations (“ASC 805”). The acquired assets and assumed liabilities were recorded at their estimated fair values. The Company determined the estimated fair values with the assistance of valuations performed by a third-party specialist, discounted cash flow analysis, and estimates made by management.
The acquisition strengthens the Company’s capabilities in inline wafer contamination monitoring, materials characterization, and unique surface charge metrology. The goodwill recognized reflects the anticipated benefits from expanding the Company’s product portfolio and its growth opportunities in both new and existing markets. As the purchase price exceeded the fair value of Semilab USA’s identifiable net assets, goodwill was recorded in connection with the transaction. The Company does not expect the goodwill to be deductible for income tax purposes.
A portion of the overall purchase price was allocated to acquired intangible assets. Amortization expense associated with acquired intangible assets is not deductible for tax purposes. Therefore, a deferred tax liability of $46.6 million was established primarily for the future amortization of these intangibles and is included in “other long-term liabilities” in the table below.
The inventory fair value step‑up is non‑recurring and is recognized as an increase to cost of revenue as the related inventory is sold. For the year ended January 3, 2026, the Company recognized $4.0 million of expense related to the step‑up. During the nine months ended September 30, 2026, the Company recognized $7.3 million of expense related to the step-up.
10
The remaining balance of approximately $1.8 million is expected to be recognized over the estimated sell‑through period of one year following the Acquisition Date.
The following table summarizes the preliminary purchase price allocation of the fair values of the assets acquired and liabilities assumed:
8,876
Accounts receivable
26,129
Inventories
33,838
Prepaid expenses and other current assets
843
Property, plant and equipment
2,058
Intangible assets
210,000
3,592
(487
Accrued expenses and other current liabilities
(8,270
Other long-term liabilities
(51,668
Total identifiable net assets
224,911
295,551
During the third quarter of 2026, the Company recorded measurement-period adjustments related to the finalization of certain acquired net assets and closing consideration, resulting in a $17.9 million decrease in goodwill.
The following table sets forth the preliminary amounts, allocated to the intangible assets identified and their estimated useful lives as of the Acquisition Date:
Fair Value
Weighted Average Useful Life
(in years)
Developed technology
103,000
7.0
Customer relationships
82,000
6.0
Backlog
20,000
1.3
Tradename
5,000
8.0
Total amortizable intangible assets
The developed technology intangible assets were valued using the relief-from-royalty method under the income approach, which estimates value based on the royalty a market participant would pay to license the technology. Under this approach, the after‑tax royalty savings attributable to ownership represent the economic benefit of the asset. The key assumptions used in the valuation included the estimated royalty rate, projected revenue attributable to the developed technology, the expected useful life of the asset, and a discount rate reflecting the risks associated with the projected cash flows. The assets are amortized on a straight‑line basis over their estimated 7‑year useful life, which approximates the expected pattern of economic benefits.
The customer relationships and backlog intangible assets were valued using the multi-period excess earnings method under the income approach, which isolates the net cash flows attributable to each asset and discounts them to present value. Significant assumptions included projected customer revenue and attrition rates, estimated operating margins, contributory asset charges, the expected useful life of the asset, and a discount rate reflecting the risks associated with the asset‑specific cash flows. The customer relationship asset is amortized on a straight-line basis over its 6‑year estimated life to reflect the pattern of expected economic benefits. The backlog asset is amortized on a straight-line basis over its 1.3 year estimated life to reflect the pattern of expected economic benefits.
There were no significant contingencies assumed as part of the acquisition.
The purchase price allocation for the Semilab USA acquisition is preliminary and reflects management’s current estimates of the fair value of the assets acquired and liabilities assumed in accordance with ASC 805. The Company is still evaluating certain items within the measurement period. Accordingly, the provisional amounts recognized for the acquired net assets are subject to change during the remainder of the measurement period (which will not exceed 12 months from the Acquisition Date). Any such revisions or changes may be material.
11
From the Acquisition Date through January 3, 2026, Semilab USA contributed $8.6 million of revenue and an operating loss of $6.2 million to the Company’s consolidated results. During the three and nine months ended September 30, 2026, Semilab USA contributed $22.5 million and $68.6 million of revenue, respectively, and an operating loss of $2.8 million and $11.8 million, respectively, to the Company’s consolidated results.
NOTE 3. Fair Value Measurements
Recurring Fair Value Measurements
The following tables present information about the Company’s assets and liabilities that are regularly measured and carried at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value, which is described further within Note 4, “Fair Value Measurements” to the consolidated financial statements in the 2025 Form 10-K:
Level 1
Level 2
Assets:
Cash and cash equivalents:
Federal and municipal notes and bonds
Cash
219,941
Money market funds
34
Asset-backed securities
Certificates of deposit
Commercial paper
180,702
Corporate bonds
Total cash and cash equivalents
219,975
Marketable Securities:
259,865
169,424
293,172
128,333
Total marketable securities
Other assets:
Foreign currency forward contracts
477
898,682
1,031,973
1,930,655
12
January 3, 2026
40,415
245,130
5,118
53,373
2,083
250,248
95,871
149,554
47,338
32,204
64,407
89
389,463
639,711
Items classified within Level 1 of the fair value hierarchy are valued using quoted prices in active markets for identical assets or liabilities. The Company’s marketable securities, comprised of Level 2 available-for-sale debt securities, are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. The foreign currency forward contracts are primarily measured based on the foreign currency spot and forward rates quoted by the banks or foreign currency dealers.
There were no impairments of the Company’s assets measured and carried at fair value during the three and nine months ended September 30, 2026 and September 27, 2025. There were no changes in valuation techniques during the three and nine months ended September 30, 2026 and September 27, 2025.
Following the Rigaku Transaction, the Company owns shares of common stock of Rigaku, which is publicly traded on the Tokyo Stock Exchange. The investment is measured at fair value on a recurring basis using the unadjusted quoted market price in the active market for the identical security, translated into U.S. dollars at the closing spot exchange rate at the reporting date, and is therefore classified within Level 1 of the fair value hierarchy. The Company’s investment in Rigaku is subject to contractual transfer restrictions for three years following the August 10, 2026 closing, subject to customary exceptions. Because the restrictions apply to the Company as the holder and are not characteristics of the shares, they are not reflected in the fair value measurement. At September 30, 2026, the fair value of the investment was $678.7 million. See Note 2, “Acquisitions and Investments” for information regarding the Company's fair value option election and the gains and losses recognized in net income.
There were no transfers into or out of Level 1 during the three and nine months ended September 30, 2026. There were no impairments of the Company's equity investments during the three and nine months ended September 30, 2026 and September 27, 2025. There were no changes in valuation techniques during the three and nine months ended September 30, 2026 and September 27, 2025.
Financial Instruments Not Measured at Fair Value on a Recurring Basis
The Company reports its financial instruments at fair value with the exception of its 2031 Notes. The estimated fair value of the 2031 Notes was determined based on the trading price of the 2031 Notes as of the last day of trading for the period. The Company classifies the fair value of the 2031 Notes as a Level 2 measurement, as the 2031 Notes are not actively traded in the market. On or after March 1, 2031, until the close of business on the second Scheduled Trading Day (as defined in the Indenture governing the 2031 Notes, which is further described in Note 7 below) immediately before the maturity date, the 2031 Notes will be convertible at the option of the noteholders at any time.
At September 30, 2026 the carrying value, net of unamortized debt discount and issuance costs, and estimated fair values of the 2031 Notes are as follows:
13
Carrying Value, net
Estimated Fair Value
Senior Convertible Notes:
2031 Notes
1,673,190
Total senior convertible notes
Assets Measured at Fair Value on a Non-Recurring Basis
At September 30, 2026 and January 3, 2026, the Company held investments of $8.0 million in the equity of a privately-held company. This non-marketable equity investment is recorded at fair value on a non-recurring basis and is classified as a Level 3 asset in “Other assets” on the Condensed Consolidated Balance Sheets. This non-marketable equity investment is generally accounted for under the measurement alternative, defined as cost, less impairments, adjusted for subsequent observable price changes and is periodically assessed for impairment when events or circumstances indicate that decline in value may have occurred. As of September 30, 2026, there have been no impairments recorded for the non-marketable equity investment.
NOTE 4. Marketable Securities
At September 30, 2026 and January 3, 2026, marketable securities are categorized as follows:
Amortized Cost
Gross UnrealizedGains
Gross UnrealizedLosses
EstimatedFair Value
260,592
(729
169,586
(172
293,471
(301
128,934
22
(623
852,583
36
(1,825
149,004
551
(1
47,243
95
32,188
16
64,214
193
292,649
855
As of September 30, 2026, all of the Company’s marketable securities are available to the Company for use in its current operations. As a result, the Company has classified all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date. The following table shows the fair value of the Company’s marketable securities, by contractual maturity, as of September 30, 2026:
Due within one year
713,080
233,043
Due after one through five years
137,714
60,460
The aggregate fair value of marketable securities with unrealized losses was $702.6 million and $21.2 million as of September 30, 2026 and January 3, 2026, respectively. All unrealized losses are reported in Stockholders’ Equity under the caption “Accumulated other comprehensive loss.” As of September 30, 2026 and January 3, 2026, 229 investments and 11 investments were in an unrealized loss position, respectively, for less than a year and these losses are considered temporary. As of September 30, 2026 and January 3, 2026, no investments and two investments were in an unrealized loss position, respectively, for greater than a year. The Company has the ability and intent to hold these investments until a recovery of their amortized cost, which may not occur until maturity. The Company expects these securities are subject to minimal credit risk. As a result, the Company did not record any charges for credit-related impairments for its available-for-sale securities for the three and nine months ended September 30, 2026 and September 27, 2025.
14
NOTE 5. Derivative Instruments and Hedging Activities
The Company, when it considers it to be appropriate, enters into forward contracts to hedge the economic exposure arising from foreign currency denominated transactions. These contracts are typically denominated in euro, Chinese renminbi, Japanese yen, Korean won, Singapore dollars and Taiwanese dollars. Foreign currency forward contracts are not designated as hedges for accounting purposes, and therefore, the change in fair value is recorded in “Other (expense) income, net,” in the Condensed Consolidated Statements of Operations. The Company records its forward contracts at fair value in either “Prepaid expenses and other current assets, net” or “Other current liabilities” in the Condensed Consolidated Balance Sheets.
The dollar equivalent of the U.S. dollar forward contracts notional amount and related fair values as of September 30, 2026 and January 3, 2026 were as follows:
Notional amount
85,107
47,361
Fair value of asset
NOTE 6. Balance Sheet Components
Inventories, net of reserves are comprised of the following:
Materials
313,419
208,061
Work-in-process
80,498
59,764
Finished goods
30,263
30,439
Total inventories, net
Property, Plant and Equipment
Property, plant and equipment, net is comprised of the following:
Machinery and equipment
98,424
95,151
Land and building
47,672
47,770
Computer equipment and software
44,699
40,635
Leasehold improvements
25,192
24,040
Furniture and fixtures
4,505
3,920
Total property, plant and equipment, gross
220,492
211,516
Accumulated depreciation
(98,994
(84,332
Total property, plant and equipment, net
For the three and nine months ended September 30, 2026, depreciation expense was $5.8 million and $17.4 million, respectively. For the three and nine months ended September 27, 2025, depreciation expense was $5.0 million and $15.2 million, respectively.
NOTE 7. Debt Obligations
Indenture and Notes
On May 21, 2026, the Company issued $1.5 billion aggregate principal amount of 2031 Notes. The 2031 Notes were issued pursuant to an Indenture, dated May 21, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). The issuance of the 2031 Notes included the exercise in full of the initial purchasers’ option to purchase up to an additional $200 million aggregate principal amount of 2031 Notes.
The Company offered and sold the 2031 Notes to the initial purchasers in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and for resale by the initial
15
purchasers to persons reasonably believed to be qualified institutional buyers pursuant to the exemption from registration provided by Rule 144A under the Securities Act.
The net proceeds from the offering were approximately $1.47 billion after deducting the initial purchasers’ discount and commissions but before offering expenses payable.
The Company used (i) approximately $89.0 million of the net proceeds to fund the cost of entering into the capped call transactions described below, (ii) approximately $205.0 million of the net proceeds to repurchase 805 thousand shares of Common Stock concurrently with the pricing of the offering in privately negotiated transactions effected with or through one of the initial purchasers or one or more of its affiliates, at a price per share equal to $254.53, the last reported sale price per share of Common Stock on the NYSE on May 18, 2026 and (iii) the remaining net proceeds for general corporate purposes, which included financing the Rigaku Transaction.
The 2031 Notes will mature on June 1, 2031, unless earlier converted, redeemed or repurchased. The 2031 Notes will not bear regular interest, and the principal amount of the 2031 Notes will not accrete. After giving effect to the initial purchasers’ discount and issuance costs, the 2031 Notes have an effective interest rate of 0.39%. However, special interest and additional interest, if any, may accrue on the 2031 Notes at a combined rate per annum not exceeding 0.50% upon the occurrence of certain events as described in the Indenture. As of September 30, 2026, the if-converted value of the 2031 Notes did not exceed the aggregate principal amount.
Beginning on March 1, 2031 and until the close of business on the second Scheduled Trading Day (as defined in the Indenture) immediately before the maturity date, the 2031 Notes will be convertible at the option of the noteholders at any time. If holders convert, we will settle conversions by paying cash up to the aggregate principal amount of the 2031 Notes to be converted and paying or delivering, as the case may be, cash, shares, or a combination thereof, at our election, in respect of the remainder, if any, of our conversion obligation in excess of the aggregate principal amount of the 2031 Notes being converted. Any 2031 Notes that remain outstanding at maturity are required to be repaid in cash.
Before March 1, 2031, noteholders will have the right to convert their 2031 Notes only under the following circumstances:
As of September 30, 2026, none of the foregoing conditions permitting early conversion of the 2031 Notes had been satisfied. Accordingly, the 2031 Notes were not convertible at the option of the noteholders as of such date, and the Company has classified the 2031 Notes as a non-current liability.
The Company may not redeem the 2031 Notes at its option at any time before June 6, 2029. The Company will have the option to redeem the 2031 Notes, in whole or in part (subject to the partial redemption limitation set forth in the Indenture), at any time, and from time to time, on or after June 6, 2029 and before the 31st Scheduled Trading Day immediately before the maturity date, at a cash redemption price equal to the principal amount of the 2031 Notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date, but only if the Last Reported Sale Price per share of the Common Stock exceeds 130% of the conversion price on (1) each of at least 20 Trading Days, whether or not consecutive, during the 30 consecutive Trading Days ending on, and including, the Trading Day immediately before the date the Company sends the related redemption notice; and (2) the Trading Day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change (as defined in the Indenture) with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. Pursuant to the partial redemption limitation, the Company may not elect to redeem less than all of the outstanding 2031 Notes unless at least $100.0 million aggregate principal amount of 2031 Notes are outstanding and not subject to redemption as of the time it sends the related redemption notice.
The conversion rate for the 2031 Notes will initially be 2.6192 shares of Common Stock per $1,000 principal amount of 2031 Notes, which is equivalent to an initial conversion price of approximately $381.80 per share of Common Stock. The conversion rate is subject to adjustment upon certain events specified in the Indenture but will not be adjusted for any accrued or unpaid interest. In addition, upon a Make-Whole Fundamental Change, the Company will, under certain circumstances, increase the applicable conversion rate for a holder that elects to convert its 2031 Notes in connection with such Make-Whole Fundamental Change. No adjustment to the conversion rate will be made if the Stock Price (as defined in the Indenture) in such Make-Whole Fundamental Change is either less than $254.53 per share or greater than $2,750.00 per share. The Company will not increase the conversion rate to an amount that exceeds 3.9288 shares per $1,000 principal amount of 2031 Notes, subject to adjustment as set forth in the Indenture. Based on the initial conversion rate, the 2031 Notes are initially convertible into approximately 3.9 million shares of the Common Stock (based on an aggregate principal amount of $1.5 billion). Assuming the maximum conversion rate of 3.9288 shares per $1,000 principal amount in connection with a Make Whole Fundamental Change, the 2031 Notes would be convertible into a maximum of approximately 5.9 million shares of Common Stock, subject to adjustment as set forth in the Indenture.
If certain corporate events that constitute a Fundamental Change (as defined in the Indenture) occur, then, subject to certain exceptions, noteholders may require the Company to repurchase their 2031 Notes in whole or in part for cash at a price equal to the principal amount of the 2031 Notes to be repurchased, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the Fundamental Change Repurchase Date (as defined in the Indenture). The Indenture governing the 2031 Notes contains customary terms and covenants, including those limiting the Company’s ability to consolidate with or merge into, or sell, lease or otherwise transfer substantially all of its assets, as well as customary events of default, each as defined in the Indenture.
The 2031 Notes are presented as “2031 Notes, net” within non-current liabilities on the condensed consolidated balance sheet as of September 30, 2026 and are carried at amortized cost. The Company evaluated the terms of the 2031 Notes under applicable accounting guidance and concluded that the 2031 Notes are appropriately accounted for as a single liability instrument, with no bifurcation or other separate accounting required.
The initial purchasers’ discount of $30 million is treated as a debt issuance cost for financial reporting purposes and as original issue discount for U.S. federal income tax purposes. Accordingly, the Company established a deferred tax asset of approximately $6.5 million at issuance. The $30 million of original issue discount is deductible for tax purposes over the term of the notes under Section 163 of the Internal Revenue Code of 1986, as amended.
The 2031 Notes consisted of the following components:
Principal
1,500,000
Unamortized debt issuance costs
(26,821
Net carrying amount of the liability component
As of September 30, 2026, the Company had unamortized debt issuance costs, including the initial purchasers’ discount, which are being amortized to interest expense over the contractual term of the 2031 Notes using the effective interest method. The remaining amortization period is approximately five years, through the maturity date of June 1, 2031. Such amortization represents non-cash interest expense and will be recognized over the remaining term of the 2031 Notes. Amortization of the debt issuance costs was $1.4 million and $2.1 million during the three and nine months ended September 30, 2026, respectively.
The future contractual principal payments related to the 2031 Notes are as follows. As the 2031 Notes do not bear regular interest, the table below reflects contractual principal repayments only and excludes non‑cash interest expense associated with the amortization of debt issuance costs.
Fiscal Years
(in millions)
2027
2028
2029
2030
Thereafter
1,500
Total Payments
17
Capped Call Transactions
In May 2026, in connection with the pricing of the 2031 Notes and the exercise by the initial purchasers of their option in full to purchase additional 2031 Notes, respectively, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with several financial institutions, including one or more of the initial purchasers and/or their respective affiliates (the “Option Counterparties”).
The Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the 2031 Notes, approximately 3.9 million shares of Common Stock, which corresponds to the number of shares initially underlying the 2031 Notes based on the initial conversion rate. The Capped Call Transactions are expected generally to reduce the potential dilution to the Common Stock upon any conversion of the 2031 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2031 Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the Capped Call Transactions will initially be $509.06 per share of Common Stock, which represents a premium of 100% over the last reported sale price of the Common Stock of $254.53 per share on May 18, 2026, and is subject to certain adjustments under the terms of the Capped Call Transactions.
The Capped Call Transactions are separate transactions (in each case entered into by the Company with the Option Counterparties), and are not part of the terms of the 2031 Notes and will not change the noteholders’ rights under the 2031 Notes. Noteholders will not have any rights with respect to the Capped Call Transactions. The Company concluded that the Capped Call Transactions met the criteria for equity classification because they were indexed to the Common Stock and the Company has the discretion to settle the Capped Call Transactions in shares or cash. As a result, the $89.0 million paid was recorded as a reduction to additional paid-in-capital within the Company’s condensed consolidated balance sheet.
The Company structured the Capped Call Transactions as tax-integrated for federal income tax purposes pursuant to applicable U.S. Treasury Regulations. Accordingly, the $89.0 million in gross cost of the purchased Capped Call Transactions will be deductible for income tax purposes over the life of the option. As a result, the Company established a deferred income tax asset of $19.3 million at inception, with a corresponding offset to additional paid-in capital.
Indebtedness
On April 20, 2026, in connection with the Rigaku Transaction, we entered into a commitment letter with Goldman Sachs Bank USA (“Goldman Sachs”) for a senior secured 364-day $500 million bridge term loan credit facility (the “Bridge Commitment”). Following the issuance of the 2031 Notes and Capped Call Transactions, the Company terminated the Bridge Commitment in full on May 21, 2026, and no amounts were drawn thereunder. The Company incurred total costs of $4.4 million in connection with the Bridge Commitment, all of which were expensed as incurred and recorded in “Other (expense) income, net” in the Condensed Consolidated Statements of Operations during the six months ended June 30, 2026. No amounts were incurred during the three months ended September 30, 2026.
NOTE 8. Commitments and Contingencies
Warranty Reserves
The Company generally provides a warranty on its products for a period of 12 to 14 months against defects in material and workmanship. The Company estimates the costs that may be incurred during the warranty period and records a liability in the amount of such costs at the time revenue is recognized. The Company’s estimate is based primarily on historical experience. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. Warranty provisions are generally related to current period sales. Settlements of warranty reserves are generally associated with sales that occurred during the 12 to 14 months prior to the period-end.
Changes in the Company’s warranty reserves are as follows:
10,292
10,858
Accruals
12,234
9,858
Usage
(10,421
(9,522
Balance, end of the period
12,105
11,194
Warranty reserves are reported in the Condensed Consolidated Balance Sheets under the captions “Accrued liabilities” and “Other non-current liabilities.”
18
Legal Matters
From time to time, the Company is subject to legal proceedings and claims in the ordinary course of business. The Company does not believe that any current legal matters will have a material adverse effect on our financial position, results of operations or cash flows.
Line of Credit
The Company had a credit agreement with a bank that provided for a variable-rate line of credit secured by the marketable securities the Company had with the bank. At January 3, 2026, the Company was permitted to borrow up to 70.0% of the value of eligible securities held at the time the line of credit was accessed, up to a maximum of $100.0 million. The available line of credit as of January 3, 2026 was $100.0 million with an available interest rate of 4.3%. The Company terminated this line of credit in the first quarter of 2026, and did not utilize the line of credit while it was active.
Leases
As of September 30, 2026, there were no material changes in the Company’s leases from those disclosed in the 2025 Form 10-K, other than those described below.
On June 18, 2026, the Company entered into a lease agreement (the “Lease”) for a new corporate headquarters facility located at 3000 Minuteman Road in Andover, Massachusetts. The leased premises consist of approximately 159,947 rentable square feet and will replace the Company’s current headquarters in Wilmington, Massachusetts. The Lease has an initial term of approximately 13 years and is expected to commence in 2027, upon substantial completion of tenant improvements or no later than 12 months following the contractual delivery date, as defined in the Lease. The Lease includes an initial rent of approximately $17.00 per square foot, subject to annual increases of 3%, as well as customary rent abatement periods and phased rent commencement provisions during the early years of the Lease term. Total undiscounted Lease payments over the initial Lease term are expected to be approximately $36.4 million. As of September 30, 2026, the Lease had not yet commenced, and therefore no right-of-use asset or corresponding lease liability has been recognized in the Company’s condensed consolidated financial statements.
NOTE 9. Revenue
The following table represents a disaggregation of revenue by timing of revenue:
Point-in-time
387,237
199,831
981,305
686,524
Over-time
22,511
18,362
63,521
51,873
Total revenue
The following table lists the different sources of revenue:
(in thousands, except for percentages)
Systems and software
358,316
87.4
%
173,795
79.7
899,513
86.1
619,451
83.9
Parts
28,465
6.9
23,930
11.0
83,728
61,955
8.4
Services
22,967
5.6
20,468
9.4
61,585
5.9
56,991
7.7
Total revenue*
100.0
*The sum of the individual percentages may not equal 100% due to rounding.
See Note 13, “Segment Reporting and Geographic Information” for additional discussion of the Company’s disaggregated revenue by geography.
Contract Assets and Contract Liabilities
Contract assets consist of amounts we have not invoiced but have completed the related performance obligation. These amounts generally arise from variances between the contractual payment terms and the transaction price assigned to the open
19
performance obligations (e.g., we have recognized revenue in an amount greater than the amount that is billable under the contract). The contract assets amounts are recorded in “Accounts receivable” in the Condensed Consolidated Balance Sheets. As of September 30, 2026 the Company had no contract assets, and as of January 3, 2026, the Company had contract assets of $3.5 million.
The Company records contract liabilities when the customer has been billed in advance of the Company completing its performance obligations primarily with respect to liabilities related to service contracts and installation. For contracts that have a duration of one year or less, these amounts are recorded as “Deferred revenue” in the Condensed Consolidated Balance Sheets. For contracts with a duration longer than one year, deferred revenue is recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheets. As of September 30, 2026 and January 3, 2026, the Company carried a long-term deferred revenue balance of $10.2 million and $6.3 million, respectively, within “Other non-current liabilities” in the Condensed Consolidated Balance Sheets.
Changes in deferred revenue were as follows:
44,592
43,545
38,031
37,836
Deferral of revenue
36,921
14,190
77,715
65,806
Recognition of current year deferred revenue
(4,003
(10,937
(23,492
(40,124
Recognition of prior period deferred revenue
(21,870
(10,181
(36,614
(26,901
55,640
36,617
NOTE 10. Share-Based Compensation
The following table presents the detail of share-based compensation expense amounts included in the Company’s Condensed Consolidated Statement of Operations:
1,187
1,028
3,355
3,030
1,226
1,203
4,154
3,557
1,232
1,039
3,586
3,029
5,160
3,616
14,736
10,284
478
Total share-based compensation expense
As of September 30, 2026, there was $50.1 million of total unrecognized compensation cost related to restricted stock units granted under the Company’s stock plans. That cost is expected to be recognized over a weighted average period of 1.7 years following September 30, 2026.
NOTE 11. Income Taxes
The Company recorded an income tax provision of $18.1 million and $30.8 million for the three and nine month periods ended September 30, 2026, as compared to $3.8 million and $17.1 million for the three and nine month periods ended September 27, 2025.
The Company’s effective tax rate was 27.9% and 18.0% for the three and nine month periods ended September 30, 2026, respectively, compared to 12% for both the three and nine month period ended September 27, 2025. The effective tax rate for the three and nine month periods ended September 30, 2026 was impacted by various tax items, primarily the tax impact associated with the unrealized loss on the Company’s investment in Rigaku for which no benefit was recognized due to a valuation allowance, which increased the effective tax rate by 10.8 and 3.5 percentage points, respectively.
The Company’s effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to the impact of foreign taxes, including the Pillar Two global minimum tax, the tax impact associated with the unrealized loss on the Company’s
20
investment in Rigaku, tax benefits associated with the Foreign Derived Intangible Income (“FDII”) deductions, federal research and development tax credits, foreign tax credits, and excess tax benefits associated with equity compensation.
NOTE 12. Earnings Per Share
Basic earnings per share is calculated using the weighted average number of shares of Common Stock outstanding during the period. Restricted stock units and employee stock purchase grants are included in the calculation of diluted earnings per share, except when their effect would be anti-dilutive. For the three and nine months ended September 30, 2026, no units and 10 thousand, respectively, restricted stock units were excluded from the computation of diluted earnings per share as their impact would have been antidilutive. For the three and nine months ended September 27, 2025, 101 thousand and 80 thousand, respectively, restricted stock units were excluded from the computation of diluted earnings per share as their impact would have been antidilutive. For the three and nine months ended September 30, 2026, 3.9 million and 1.9 million shares issuable upon conversion of the Company’s convertible notes were excluded from the computation of diluted earnings per share because the average market price of Common Stock during each period was below the conversion price.
The Company’s basic and diluted earnings per share amounts are as follows:
(in thousands, except for per share data)
Numerator:
Denominator:
Basic earnings per share - weighted average shares outstanding
Effect of potential dilutive securities:
Restricted stock units and employee stock purchase grants - dilutive shares
208
83
247
134
Diluted earnings per share - weighted average shares outstanding
NOTE 13. Segment Reporting and Geographic Information
The Company is organized and operates as one operating and reportable segment: the design, development, manufacture and support of high-performance control metrology, defect inspection, lithography and data analysis systems used by microelectronics device manufacturers. This determination is based on the management approach which designates internal information regularly available to the Chief Operating Decision Maker (“CODM”) for making decisions and assessing performance as the source of determination of the Company’s reportable segments. The Company’s CODM, the Chief Executive Officer, reviews financial information presented on a consolidated basis for the purpose of making operating decisions and assessing financial performance. The CODM uses net income as the measure of profit or loss to allocate resources and assess performance. The measure of segment assets is reported on the balance sheet as total assets.
21
The table below presents the Company’s consolidated operating results including significant segment expenses:
Less:
Adjusted cost of revenue (1)
173,746
100,267
450,588
335,289
Adjusted research and development (2)
44,780
32,492
118,757
96,505
Adjusted sales and marketing (1)
23,823
68,343
Adjusted general and administrative (1)
33,945
22,274
92,992
66,707
Other segment items:
Restructuring and other (3)
12,089
11,377
42,753
38,550
Merger and acquisitions related (3)
5,609
2,547
19,175
5,212
20,307
59,705
(1) Excludes restructuring and other expenses and merger and acquisition related expenses
(2) Excludes merger and acquisition related expenses or benefits
(3) The Company excludes these expenses in order to provide better comparability between periods as they are not representative of the Company’s ongoing operations.
The Company’s significant operations outside the United States include sales, service and application offices in Asia and Europe. For geographical revenue reporting, revenue is attributed to the geographic location to which the product is shipped. Revenue by geographic region is as follows:
Revenue from customers:
Taiwan
174,972
59,243
365,391
227,441
South Korea
82,266
44,864
249,576
220,828
United States
50,433
37,793
218,533
90,946
Europe
17,627
10,590
46,945
39,979
China
32,069
27,359
63,833
56,872
Southeast Asia
31,754
22,329
57,253
44,179
Japan
20,627
16,015
43,295
58,152
The following customers accounted for 10.0% or more of total revenue for the indicated periods:
Customer A
16.8
20.7
Customer B
14.5
17.8
Customer C
14.3
14.4
Customer D
11.5
^
^ The customer accounted for less than 10.0% of total revenue during the period.
Three customers’ accounts receivable balances were individually greater than 10.0% of net accounts receivable at September 30, 2026, representing, in the aggregate, approximately 39.8% of the Company’s total accounts receivable.
One customer’s accounts receivable balances was individually greater than 10.0% of net accounts receivable at January 3, 2026, representing approximately 12.2% of the Company’s total accounts receivable.
Substantially all of the Company’s long-lived assets are located within the United States of America.
NOTE 14. Share Repurchase Authorization
In February 2024, the Board approved a share repurchase authorization (the “2024 Authorization”), which allows the Company to repurchase up to $200 million worth of shares of Common Stock. Under the 2024 Authorization, repurchases may be made through both public market and private transactions from time to time. Any amount paid to repurchase the shares in excess of par value, including transaction costs, would be recorded directly as a decrease to additional paid-in capital. During the three and nine months ended September 30, 2026, no shares of Common Stock were repurchased under the 2024 Authorization. During the three and nine months ended September 27, 2025, no shares and 492 thousand shares, respectively, of Common Stock were repurchased under the 2024 Authorization. At September 30, 2026, there was $99.9 million available for future share repurchases under the 2024 Authorization.
Additionally, in May 2026, the Board approved a share repurchase authorization (the “2026 Authorization”), which allowed the Company to repurchase up to $300 million worth of shares of Common Stock solely in connection with the 2031 Notes issuance. During the three and nine months ended September 30, 2026, no shares and 805 thousand shares, respectively, of Common Stock were repurchased under the 2026 Authorization. The 2026 Authorization is no longer in effect and any and all remaining and unused amount under the 2026 Authorization is no longer available for repurchase.
NOTE 15. Restructuring and Other
From time to time, the Company approves restructuring plans, which include workforce reductions, to streamline operations and align the Company’s cost structure with its business outlook. These restructuring plans may result in charges to cost of revenue for streamlining of certain manufacturing activities and other charges, including inventory write-downs primarily related to the exit of older product lines. Charges to operating expenses primarily include employee severance costs that are paid during the period incurred, charges for streamlining of certain operating activities and impairment charges such as plant, property and equipment.
Restructuring and other expenses recorded in the Condensed Consolidated Statements of Operations are as follows:
10,912
7,303
32,606
27,129
Operating expenses
Total restructuring and other
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this Form 10-Q, or incorporated by reference in this Form 10-Q, of Onto Innovation Inc. (referred to in this Form 10-Q, together with its consolidated subsidiaries, unless otherwise specified or suggested by the context, as the “Company,” “Onto Innovation,” “we,” “our” or “us”) are considered “forward-looking statements” or are based on “forward-looking statements,” including, but not limited to, those concerning:
Statements contained or incorporated by reference in this Form 10-Q that are not purely historical are forward-looking statements and are subject to safe harbors under Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as, but not limited to, “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “plan,” “should,” “may,” “could,” “will,” “would,” “forecast,” “project” and words or phrases of similar meaning, as they relate to our management or us.
Forward-looking statements contained herein reflect our current expectations, assumptions and projections with respect to future events and are subject to certain risks, uncertainties and assumptions. Actual results may differ materially and adversely from those included in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond Onto Innovation’s control. Such factors include, but are not limited to, the Company’s ability to leverage its resources to improve its position in its core markets; its ability to weather difficult economic environments; its ability to open new market opportunities and target high-margin markets; the strength/weakness of the back-end and/or front-end semiconductor market segments; fluctuations in customer capital spending; the Company’s ability to effectively manage its supply chain and adequately source components from suppliers to meet customer demand; the effects of political, economic, legal, and regulatory changes or uncertainties, changes in U.S. tariff and trade policy and related retaliatory actions, and geopolitical conflicts, including the ongoing conflict involving Israel, the U.S., Iran and other actors, on the Company’s global operations; the Company’s ability to adequately protect its intellectual property rights and maintain data security; the effects of natural disasters or public health emergencies on the global economy and on the Company’s customers, suppliers, employees, and business; its ability to effectively maneuver global trade issues and changes in trade and export regulations, tariffs and license policies; the Company’s ability to maintain relationships with its customers and manage appropriate levels of inventory to meet customer demands; the Company’s ability to realize the anticipated benefits of the Rigaku Transaction (as defined below), including as a result of fluctuations in the price of the Rigaku common stock; and the Company’s ability to successfully integrate acquired businesses and technologies, including the business of Semilab USA and to realize the anticipated benefits of such acquisitions. Additional information and considerations regarding the risks faced by Onto Innovation are available in our Annual Report on Form 10-K for the fiscal year ended January 3, 2026 (the “2025 Form 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026, in Part II, Item 1A. “Risk Factors” and elsewhere in this Form 10-Q, and in the other filings that we make with the SEC from time to time. Forward-looking statements reflect our position as of the date of this Form 10-Q and we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Critical Accounting Estimates
The preparation of condensed consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make judgments, assumptions and estimates that affect the amounts reported.
Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. In addition, management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Certain of these uncertainties are discussed in the 2025 Form 10-K in the Items entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” There have been no material changes in our critical accounting estimates from the information presented in Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the 2025 Form 10-K.
For more information, please see our critical accounting estimates as previously disclosed in the 2025 Form 10-K and recent accounting pronouncements discussed in Note 1, “Basis of Presentation” to the Condensed Consolidated Financial Statements include in Part 1, Item 1 of this Form 10-Q.
24
Executive Summary
We are a worldwide leader in the design, development, manufacture and support of process control tools that perform macro-defect inspection and metrology, lithography systems, and process control analytical software used by semiconductor and advanced packaging device manufacturers. We deliver comprehensive solutions throughout the semiconductor fabrication process with our families of proprietary products that provide critical yield-enhancing information, enabling microelectronic device manufacturers to drive down costs and time to market of their devices. We provide process and yield management solutions used in both wafer processing facilities, often referred to as “front-end” manufacturing, and in device packaging and test facilities, commonly referred to as “back-end” manufacturing. Our advanced process control software portfolio includes powerful solutions for standalone tools, groups of tools, or factory-wide suites to enhance productivity and achieve significant cost savings.
Our principal market is semiconductor capital equipment. Semiconductors packaged as integrated circuits (“ICs”), or “chips,” are used in consumer electronics, server and enterprise systems, mobile computing (including smart phones and tablets), data storage devices, and embedded automotive and control systems. Our core focus is the measurement and control of the structure, composition, and geometry of semiconductor devices as they are fabricated on silicon wafers to improve device performance and manufacturing yields.
Our products and services are used by our customers who manufacture many types of ICs for a multitude of applications, each having unique manufacturing challenges. This includes ICs to enable information processing and management (logic ICs), memory storage (NAND, 3D-NAND, NOR, and DRAM), analog devices (e.g., Wi-Fi and 5G radio ICs, power devices), MEMS sensor devices (accelerometers, pressure sensors, microphones), image sensors, and other end markets including components for AI, hard disk drives, LEDs, and power management.
The semiconductor and electronics industries have also been characterized by constant technological innovation. We believe that, over the long term, our customers will continue to invest in advanced technologies and new materials to enable smaller design rules and higher density applications that fuel demand for process control equipment.
The following table summarizes certain key financial information for the periods indicated below:
June 30,
(in thousands, except for percentages and per share data)
343,129
183,254
Gross profit as a percentage of revenue
54.8
53.4
119,704
Diluted earnings per share
1.21
Our cash, cash equivalents and marketable securities balance increased to $1.25 billion at September 30, 2026, compared to $639.6 million at January 3, 2026. This increase was primarily the result of $1.2 billion of cash provided by financing activities and $166.6 million of cash generated from operating activities. These increases were offset by cash used in investing activities of $1.3 billion, which included the purchase of the Company’s equity investment in Rigaku of $719.5 million. Employee headcount at September 30, 2026 was approximately 1,952.
On May 21, 2026, we issued $1.5 billion aggregate principal amount of 2031 Notes. The 2031 Notes were issued pursuant to the Indenture. Pursuant to the purchase agreement between the Company and the representative of the initial purchasers of the 2031 Notes, we granted the initial purchasers an option to purchase up to an additional $200 million aggregate principal amount of 2031 Notes. On May 19, 2026, the initial purchasers exercised this option in full and the 2031 Notes issued on May 21, 2026 include the additional $200 million aggregate principal amount of 2031 Notes. Also in May 2026, in connection with the pricing
25
of the 2031 Notes and the exercise by the initial purchasers of their option in full to purchase additional Notes, respectively, we entered into the Capped Call Transactions with several financial institutions, including one or more of the initial purchasers and/or their respective affiliates.
On August 10, 2026, the Company completed the Rigaku Transaction, funded with a portion of the net proceeds from the 2031 Notes and cash on hand. In connection with the Rigaku Transaction, we received the right to nominate one director to Rigaku’s board of directors.
The Company does not control Rigaku and does not consolidate Rigaku’s financial results. At initial recognition, the Company irrevocably elected the fair value option under ASC 825, Financial Instruments, for its investment in Rigaku, which is presented as “Investment in Rigaku,” a non-current asset, on the Condensed Consolidated Balance Sheets. The investment is remeasured to fair value at each reporting date based on the quoted market price of Rigaku’s common stock on the Tokyo Stock Exchange, translated into U.S. dollars at the closing spot exchange rate. All changes in the U.S. dollar fair value of the investment, including amounts attributable to changes in Rigaku’s share price and changes in the Japanese yen to U.S. dollar exchange rate, are recognized in net income within “Unrealized gain (loss) on investment in Rigaku” under “Other income (expense), net” in the Condensed Consolidated Statements of Operations. We recognized an unrealized loss of $40.8 million for the three and nine months ended September 30, 2026.
For a discussion of the risks related to our business and operations, see Part I, Item 1A - Risk Factors of the 2025 Form 10-K and Part II, Item 1A - Risk Factors of this Form 10-Q.
Results of Operations for the Three and Nine Months ended September 30, 2026 and September 27, 2025
Revenue. Our revenue is primarily derived from the sale of our systems, software licensing, services and spare parts. Our revenue of $409.7 million increased 87.8% for the three months ended September 30, 2026 as compared to the three months ended September 27, 2025, for which revenue totaled $218.2 million. For the nine months ended September 30, 2026 and September 27, 2025, our revenue totaled $1.04 billion and $738.4 million, respectively, representing a year-over-year increase of 41.5%.
The following table lists, for the periods indicated, the different sources of our revenue in dollars and as percentages of our total revenue:
Total systems and software revenue increased $185.6 million and $281.2 million for the three and nine months ended September 30, 2026, respectively, as compared to the three and nine months ended September 27, 2025, respectively. The increase was attributable to increased demand for inspection and metrology systems. The increase in total parts and services revenue for the three and nine months ended September 30, 2026, as compared to the three and nine months ended September 27, 2025, was primarily due to higher customer support activity and service contract revenue.
Gross Profit. Our gross profit has been and will likely continue to be affected by a variety of factors, including manufacturing efficiencies, provision for excess and obsolete inventory, pricing by competitors or suppliers, new product introductions, production volume, customization and reconfiguration of systems, international and domestic sales mix, system and software product mix and parts and service margins.
The following table lists, for the periods indicated, our gross profit in dollars and as percentages of our total revenue:
50.7
53.0
50.9
26
The increase in gross profit as a percentage of revenue for the three and nine months ended September 30, 2026 as compared to the three and nine months ended September 27, 2025 was primarily due to increased sales of newer product lines with higher standard margins.
Operating Expenses.
Our operating expenses consist of:
27
Total other income, net. Total other expense was $30.5 million and $21.0 million for the three and nine month periods ended September 30, 2026, as compared to total other income of $8.3 million and $24.3 million for the three and nine month periods ended September 27, 2025. The decrease in total other income, net for the three months ended September 30, 2026, as compared to the three months ended September 27, 2025, and for the nine month period ended September 30, 2026, as compared to the nine month period ended September 27, 2025, was primarily attributable to recognition of an unrealized loss in Rigaku during the period of $40.8 million.
Income Taxes. We recorded an income tax provision of $18.1 million and $30.8 million for the three and nine month periods ended September 30, 2026, respectively, compared to $3.8 million and $17.1 million for the three and nine month periods ended September 27, 2025, respectively. Our effective tax rate was 27.9% and 18.0% for the three and nine month periods ended September 30, 2026, respectively, compared to 12.0% for both the three and nine month periods ended September 27, 2025.
The following table reconciles our GAAP effective tax rate to our non-GAAP adjusted effective tax rate, which excludes the tax impact associated with the investment in Rigaku. We believe the non-GAAP adjusted effective tax rate provides useful information to investors in evaluating our effective tax rate because the changes in the fair value are driven by the market price of Rigaku’s shares and, because no tax benefit is recognized on unrealized losses due to a valuation allowance, may result in significant period to period variability in our effective tax rate. Management uses the non-GAAP adjusted effective tax rate to evaluate tax impacts from ordinary operations.
GAAP effective tax rate
27.90
18.00
Tax impact associated with the investment in Rigaku
10.8 pts.
3.5 pts.
Non-GAAP adjusted effective tax rate excluding Rigaku
17.10
14.50
There was no comparable adjustment in the 2025 periods because the investment in Rigaku occurred in 2026.
Our effective tax rate differed from the U.S. federal statutory rate of 21% primarily due to the impact of foreign taxes, including the Pillar Two global minimum tax, the tax impact associated with the unrealized loss on our investment in Rigaku, tax benefits associated with the Foreign Derived Intangible Income (“FDII”) deductions, federal research and development tax credits, foreign tax credits, and excess tax benefits associated with equity compensation.
Our future effective income tax rate depends on various factors, including changes in tax legislation, the geographic composition and amount of our pre-tax income, non-deductible expenses incurred in connection with business combinations, and research and development tax credits as a percentage of aggregate pre-tax income.
Liquidity and Capital Resources
Our cash, cash equivalents and marketable securities consist of the following in dollars for the periods indicated:
Total cash, cash equivalents and marketable securities
1,251,471
639,622
Sources and Uses of Cash
A summary of net cash and cash equivalents provided by (used in) operating, investing, and financing activities is as follows in dollars for the periods indicated:
Net cash and cash equivalents used in investing activities
Operating Activities
28
Net cash and cash equivalents provided by operating activities for the nine month period ended September 30, 2026 was $166.6 million. The net cash and cash equivalents provided by operating activities during the nine month period ended September 30, 2026 resulted primarily from net income, adjusted to exclude the effect of non-cash operating charges of $152.0 million. Significant non-cash operating charges included depreciation, amortization, share-based compensation and provision for inventory valuation. Cash provided by operating activities for the first nine months of 2026 decreased compared to the corresponding period in fiscal 2025, primarily due to timing of accounts receivable payments and higher inventory levels driven by revenue growth, partially offset by increased in accounts payable and accrued expense due to the timing of vendor payments and higher operational activity.
Investing Activities
Net cash and cash equivalents used in investing activities for the nine month period ended September 30, 2026 was $1.3 billion. During the nine month period ended September 30, 2026, net cash and cash equivalents used in investing activities included the purchase of the Company’s equity investment in Rigaku of $719.5 million, purchases of marketable securities of $987.8 million and capital expenditures of $8.8 million, offset by proceeds from maturities and sales of marketable securities of $435.0 million and acquisition related adjustments of $6.5 million.
From time to time, we evaluate whether to acquire new or complementary businesses, products or technologies. We may fund all of or a portion of the price of these investments or acquisitions in cash, stock, or a combination of cash and stock.
Financing Activities
Net cash and cash equivalents provided by financing activities for the nine month period ended September 30, 2026 was $1.2 billion. During the nine month period ended September 30, 2026, financing activities provided cash from proceeds of the 2031 Notes, partially offset by cash used for the Capped Call Transaction and repurchases of common stock, as well as for tax payments related to shares withheld to satisfy employee tax obligations in connection with the vesting of awards under share-based compensation plans.
In February 2024, the Onto Innovation Board of Directors (the “Board”) approved a share repurchase authorization (the “2024 Authorization”), which allows us to repurchase up to $200 million worth of shares of Common Stock. Under the 2024 Authorization, repurchases may be made through both public market and private transactions from time to time. Any amount paid to repurchase the shares in excess of par value, including transaction costs, would be recorded directly as a decrease to additional paid-in capital. During the three and nine month periods ended September 30, 2026, no shares of Common Stock were repurchased under the 2024 Authorization. During the three and nine months ended September 27, 2025, no shares and 492 thousand shares, respectively, of Common Stock were repurchased under the 2024 Authorization. At September 30, 2026, there was $99.9 million available for future share repurchases under the 2024 Authorization.
As of September 30, 2026, the net carrying amount of our 2031 Notes of $1.47 billion (principal balance of $1.5 billion maturing in 2031) is presented in non-current liabilities in our condensed consolidated balance sheets. If the closing price of Common Stock exceeds $496.34 (or 130% of the conversion price of $381.80) for 20 of the last 30 trading days of any future quarter, our 2031 Notes would become convertible at the option of the holders during the subsequent fiscal quarter and the debt would be reclassified to current liabilities in our consolidated balance sheets.
On April 20, 2026, in connection with the Rigaku Transaction, we entered into a commitment letter with Goldman Sachs Bank USA (“Goldman Sachs”) for a senior secured 364-day $500 million bridge term loan credit facility (the “Bridge Commitment”). Following the issuance of the 2031 Notes and Capped Call Transactions, the Company terminated the Bridge Commitment in full on May 21, 2026, and no amounts were drawn thereunder. The Company incurred total costs of $4.4 million in connection with the Bridge Commitment, all of which were expensed as incurred and recorded in “Other (expense) income, net” in the Condensed Consolidated Statements of Operations during the six months ended June 30, 2026. No amounts were incurred during the three month period ended September 30, 2026.
The Company had a credit agreement with a bank that provides for a variable-rate line of credit which was secured by the marketable securities the Company has with the bank. At January 3, 2026 the Company was permitted to borrow up to 70.0% of the value of eligible securities held at the time the line of credit would be accessed, up to a maximum of $100.0 million. The
29
available line of credit as of January 3, 2026 was $100.0 million with an available interest rate of 4.3%. The Company terminated this line of credit in the first quarter of 2026, and did not utilize the line of credit while it was active.
Our future capital requirements will depend on many factors, including the timing and amount of our revenue and our investment decisions, which will affect our ability to generate additional cash. We expect that our existing cash, cash equivalents and marketable securities will be sufficient to meet our anticipated cash requirements for working capital, capital expenditures, and other cash needs for the next 12 months following the filing of this Form 10-Q. Thereafter, if cash generated from operations and financing activities is insufficient to satisfy our working capital requirements, we may seek additional funding through bank borrowings, sales of securities or other means. A reduction in or volatility with respect to our stock price or a general market downturn could materially impact our ability to sell securities on favorable terms or at all. There can be no assurance that we will be able to raise any such capital on terms acceptable to us or at all.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in market risk from the information presented in Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” in the 2025 Form 10-K, outside of the market risks associated with the Company’s Investment in Rigaku described below.
As discussed in Note 1, “Basis of Presentation,” the Company is exposed to equity price related to its investment in Rigaku. The investment is measured at fair value based on Rigaku’s quoted market price on the Tokyo Stock Exchange. Accordingly, changes in the fair value of the investment are recognized in earnings.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in SEC rules and forms. These controls and procedures are also designed to ensure that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, we have recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Management is required to apply judgment in evaluating its controls and procedures.
We performed an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to assess the effectiveness of the design and operation of our disclosure controls and procedures under the Exchange Act as of September 30, 2026. Based on that evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of September 30, 2026 at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during our fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 1. Legal Proceedings
For a description of our material pending legal proceedings refer to the information set forth under “Legal Matters” of Note 8, “Commitments and Contingencies,” to the Condensed Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q.
Item 1A. Risk Factors.
There have been no material changes from the risk factors previously disclosed under the heading “Risk Factors” in the 2025 Form 10-K, as updated by the risk factors previously disclosed under the heading “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2026, filed with the SEC on May 5, 2026, and June 30, 2026, filed with the SEC on August 6, 2026. We may disclose additional changes to risk factors or additional factors from time to time in our future filings with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Additionally, in May 2026, the Board approved a share repurchase authorization (the “2026 Authorization”), which allowed the Company to repurchase up to $300 million worth of shares of Common Stock solely in connection with the 2031 Notes issuance. During the three and nine months ended September 30, 2026, no shares and 805 thousand shares, respectively, of Common Stock were repurchased under the 2026 Authorization. The 2026 Authorization ceased to be in effect and any and all remaining and unused amount under the 2026 Authorization is no longer available for repurchase.
For further information, see Note 14, “Share Repurchase Authorization,” of the Notes to the Condensed Consolidated Financial Statements.
In addition to our share repurchase program, we withhold shares of Common Stock associated with net share settlements to cover tax withholding obligations upon the vesting of restricted stock unit awards under the Company’s equity incentive program.
The following table provides details of Common Stock purchased during the three months ended September 30, 2026 (in thousands, except per share data):
Period
Total Number of Shares Purchased
Average Price Paid per Share
Total Number of Shares Purchased as Part of Publicly Announced Program
Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Program
July 1, 2026 to July 31, 2026
99,935
August 1, 2026 to August 31, 2026
September 1, 2026 to September 30, 2026
254.48
Three months ended September 30, 2026
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Item 5. Other Information
Rule 10b5-1 Plan Elections
During the fiscal quarter ended September 30, 2026, the following officers and directors (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K), as follows:
On August 12, 2026, Yoon Ah Oh, the Company’s Senior Vice President & General Counsel and Corporate Secretary, adopted a 10b5-1 Plan providing for the sale from time to time of an aggregate of up to 10,278 shares of Common Stock (the “Oh 10b5-1 Plan”). The duration of the Oh 10b5-1 Plan is effective until August 12, 2027, or earlier if all transactions under the Oh 10b5-1 plan are completed.
Item 6. Exhibits
Exhibit No.
Description
3.1
Amended and Restated Certificate of Incorporation of Onto Innovation Inc., dated October 25, 2019, incorporated by reference to Exhibit 3.2 to the Company’s Form 8-K filed with the SEC on October 28, 2019 (File No. 001-39110).
3.2
Amended and Restated Bylaws of Onto Innovation Inc., dated January 22, 2020, incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K filed with the SEC on January 27, 2020 (File No. 001-39110).
31.1*
Rule 13a-14(a) Certification of Chief Executive Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
Rule 13a-14(a) Certification of Chief Financial Officer of the Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*
Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents
104*
Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)
^Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.
* Filed herewith.
** Furnished herewith.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Onto Innovation Inc.
Date:
November 9, 2026
By:
/s/ Michael P. Plisinski
Michael P. Plisinski
Chief Executive Officer
/s/ Brian K. Roberts
Brian K. Roberts
Chief Financial Officer and Principal Accounting Officer
33